Bone marrow biopsy i lymphoma

European Journal of Haematology

Volumn 73, Issue 3, 2004, Pages 149-155

  Franco, Vito ^a,c   Tripodo, Claudio ^a   Rizzo, Aroldo ^b   Stella, Mario ^b   Florena, Ada Maria ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^c Istituto di Anatomia e Istologia Patologica   (Italy)

Author keywords

Bone marrow biopsy; Diagnosis; Hodgkin's lymphoma; Immunohistochemistry

Indexed keywords

BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER INCIDENCE; CANCER INFILTRATION; CANCER RISK; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EXAMINATION; CLINICAL FEATURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IATROGENIC DISEASE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LYMPHOMA; MASTOCYTOSIS; PRIORITY JOURNAL; REED STERNBERG CELL; REVIEW; RISK FACTOR; STANDARD;

BONE MARROW EXAMINATION; DIAGNOSIS, DIFFERENTIAL; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; PRACTICE GUIDELINES;

EID: 4043110511     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00292.x     Document Type: Review

References (44)

1. DE VITA VT, MAUCH PM, HARRIS NL. Hodgkin's disease. In: De VITA VT, HELLMAN S, ROSENBERG SA, eds. Cancer Principles and Practise of Oncology. Philadelphia, PA: Lippincott-Raven, 1997:2242-2283.
2. HOWARD MR, TAYLOR PR, LUCRAFT HH, TAYLOR MJ, PROCTOR SJ. Bone marrow examination in newly diagnosed Hodgkin's disease: current practice in the United Kingdom. Br J Cancer 1995;71:210-212.
3. MUNKER R, HASENCLEVER D, BROSTEANU O, HILLER E, DIEHL V. Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. J Clin Oncol 1995;13:403-409.
4. DOLL DC, RINGENBERG QS, ANDERSON SP, HEWETT JE, YARBRO JW. Bone marrow biopsy in the initial staging of Hodgkin's disease. Med Pediatr Oncol 1989;17:1-5.
5. HASENCLEVER D, DIEHL V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
6. SPECHT L, NISSEN NI. Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol 1988;41:359-367.
7. PONZONI M, FUMAGALLI L, ROSSI G, FRESCHI M, RE A, VIGANO MG, GUIDOBONI M, DOLCETTI R, MCKENNA RW, FACCHETTI F. Isolated bone marrow manifestation of HIV-associated hodgkin lymphoma. Mod Pathol 2002;15:1273-1278.
8. HOWELL SJ, GREY M, CHANG J, MORGENSTERN GR, COWAN RA, DEAKIN DP, RADFORD JA. The value of bone marrow examination in the staging of Hodgkin's lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol 2002;119:408-411.
9. MAHONEY DH Jr, SCHREUDERS LC, GRESIK MV, MCCLAIN KL. Role of staging bone marrow examination in children with Hodgkin disease. Med Pediatr Oncol 1998;30:175-177.,
10. BRUNNING RD, MCKENNA RW. Bone marrow lymphomas. In: BRUNNING RD, MCKENNA RW, eds. Tumors of the Bone Marrow. Atlas of Tumor Pathology. Third series, fascicle 9. Washington DC: Armed Forces Institute of Pathology, 1994:369-408.
11. KANAEV SV, NOVIKOV SN, ZHUKOVA LA, POZHARISSKII KM, LEENMAN EE, GERSHANOVICH ML. Risk factors for bone marrow involvement in Hodgkin's disease. Vopr Onkol 2001;47:39-44.
12. GOMEZ-ALMAGUER D, RUIZ-ARGUELLES GJ, LOPEZ-MARTINEZ B, ESTRADA E, LOBATO-MENDIZABAL E, JAIME-PEREZ JC. Role of bone marrow examination in staging Hodgkin's disease: experience in Mexico. Clin Lab Haematol 2002;24:221-223.
13. SPECTOR N, NUCCI M, OLIVEIRA DE MORAIS JC, MAIOLINO A, PORTUGAL RD, COSTA MA, PULCHERI W. Clinical factors predictive of bone marrow involvement in Hodgkin's disease. Leuk Lymphoma 1997;26:171-176.
14. RACCHI O, RAPEZZI D, FERRARIS AM, GAETANI GF. Unusual bone marrow relapse of Hodgkin's disease with typical Pel-Ebstein fever. Ann Hematol 1996;73:39-40.
15. MONTOTO S, CAMOS M, LOPEZ-GUILLERMO A et al. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer 2000;88:2142-2148.
16. KOJIMA H, TAKEI N, MUKAI Y, HASEGAWA Y, SUZUKAWA K, NAGATA M, NOGUCHI M, MORI N, NAGASAWA T. Hemophagocytic syndrome as the primary clinical symptom of Hodgkin's disease. Ann Hematol 2003;82:53-56.
17. FLORENA AM, IANNITTO E, QUINTINI G, FRANCO V. Bone marrow biopsy in hemophagocytic syndrome. Virchows Arch 2002;441:335-344.
18. RAPPAPORT H, BERARD CW, BUTLER JJ, DORFMAN RF, LUKES RJ, THOMAS LB. Report of the committee on histopathological criteria contributing to staging of Hodgkin's disease. Cancer Res 1971;31:1864-1865.
19. ELLIS ME, DIEHL LF, GRANGER E, ELSON E. Trephine needle bone marrow biopsy in the initial staging of Hodgkin disease: sensitivity and specificity of the Ann Arbor staging procedure criteria. Am J Hematol, 1989;30:115-120.
20. KROFT SH, MCKENNA RW. Bone marrow manifestations of Hodgkin's and non-Hodgkin's lymphomas and lymphoma-like disorders. In: KNOWLES DM, ed. Neoplastic Hematopathology, 2nd edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 2001:1447-1504.
21. LAMBERTENGHI-DELILIERS G, ANNALORO C, SOLIGO D, ORIANI A, POZZOLI E, QUIRICI N, LUKSCH R, POLLI EE. Incidence and histological features of bone marrow involvement in malignant lymphomas. Ann Hematol 1992;65:61-65.
22. WATANABE K, YAMASHITA Y, NAKAYAMA A, HASEGAWA Y, KOJIMA H, NAGASAWA T, MORI N. Varied B-cell immunophenotypes of Hodgkin/Reed-Sternberg cells in classic Hodgkin's disease. Histopathology 2000;36:353-361.
23. PETRELLA T, MICHIELS JF, MICHIELS R, COLLIN F, NABHOLTZ JM, FRIEDMAN S, FARGEOT P. CD 15 antigen in Hodgkin's disease. Pathol Res Pract 1989;185:886-890.
24. BENHARROCH D, DIMA E, LEVY A, OHANA-MALKA O, ARIAD S, PRINSLOO I, MEJIROVSKY E, SACKS M, GOPAS J. Differential expression of sialyl and non-sialyl-CD15 antigens on Hodgkin-Reed-Sternberg cells: significance in Hodgkin's disease. Leuk Lymphoma 2000;39:185-194.
25. KIM LH, NADARAJAH VS, PEH SC, POPPEMA S. Expression of Bcl-2 family members and presence of Epstein-Barr virus in the regulation of cell growth and death in classical Hodgkin's lymphoma. Histopathology 2004;44:257-267.
26. AMINI RM, ENBLAD G, ENGSTROM P, CHRISTENSSON B, GLIMELIUS B, SUNDSTROM C. Relapsed Hodgkin's lymphoma: immunostaining patterns in relation to survival. Leuk Lymphoma 2000;43:1253-1260.
27. PILLAI G, PEZZELLA F, GATTER K. 'Follicular' pattern of bone marrow involvement in lymphocyte-predominant Hodgkin's disease. Histopathology 2003;43:203-205.
28. LUKES RJ. Criteria for involvement of lymph node, bone marrow, spleen, and liver in Hodgkin's disease. Cancer Res 1971;31:1755-1767.
29. STEIMLE-GRAUER SA, TINGUELY M, SEADA L, FELLBAUM C, HANSMANN ML. Expression patterns of transcription factors in progressively transformed germinal centers and Hodgkin lymphoma. Virchows Arch 2003;442:284-293.
30. AXDORPH U, PORWIT-MACDONALD A, GRIMFORS G, BJORKHOLM M. Tissue eosinophilia in relation to immunopathological and clinical characteristics in Hodgkin's disease. Leuk Lymphoma 2001;42:1055-1065.
31. ENBLAD G, SUNDSTROM C, GLIMELIUS B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 1993;11:187-193.
32. TORLAKOVIC E, TORLAKOVIC G, NGUYEN PL, BRUNNING RD, DELABIE J. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol 2002;26:1343-1350.
33. FOSS HD, REUSCH R, DEMEL G, LENZ G, ANAGNOSTOPOULOS I, HUMMEL M, STEIN H. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999;94:3108-3113.
34. BROWNE P, PETROSYAN K, HERNANDEZ A, CHAN JA. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003;120:767-777.
35. REE HJ, STRAUCHEN JA, KHAN AA, GOLD JE, CROWLEY JP, KAHN H, ZALUSKY R. Human immunodeficiency virus-associated Hodgkin's disease. Clinicopathologic studies of 24 cases and preponderance of mixed cellularity type characterized by the occurrence of fibrohistiocytoid stromal cells. Cancer 1991;67:1614-1621.
36. MACAVEI I, GALATAR N. Bone marrow biopsy (BMB). III. Bone marrow biopsy in Hodgkin's disease (HL). Morphol Embryol (Bucur) 1990;36:25-32.
37. TE VELDE J, DEN OTTOLANDER GJ, SPAANDER PJ, Van DEN BERG C, HARTGRINK-GROENEVELD CA. The bone marrow in Hodgkin's disease: the non-involved marrow. Histopathology 1978;2:31-46.
38. JOSHI A, AQEL NM. Hodgkin's disease of bone marrow masquerading as a heavy plasma cell infiltration and fibrosis. Br J Haematol 2003;122:343.
39. ANWAR M, NUR S, SALEEM M, AHMAD M, ZAFAR T. Bone marrow involvement in Hodgkin's disease: the significance of non-infiltrative changes. J Pak Med Assoc 1997;47:110-113.
40. O'CARROLL DI, MCKENNA RW, BRUNNING RD. Bone marrow manifestations of Hodgkin's disease. Cancer 1976;38:1717-1728.
41. MOOG F, BANGERTER M, KOTZERKE J, GUHLMANN A, FRICKHOFEN N, RESKE SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16:603-609.
42. BANGERTER M, MOOG F, BUCHMANN I, KOTZERKE J, GRIESSHAMMER M, HAFNER M, ELSNER K, FRICKHOFEN N, RESKE SN, BERGMANN L. Whole-body 2-[18F]-fluoro-2-deoxy- D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998;9:1117-1122.
43. JERUSALEM G, BEGUIN Y, FASSOTTE MF, NAJJAR F, PAULUS P, RIGO P, FILLET G. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001;86:266-273.
44. WANG J, WEISS LM, CHANG KL, SLOVAK ML, GAAL K, FORMAN SJ, ARBER DA. Diagnostic utility of bilateral bone marrow examination. Significance of morphologic and ancillary technique study in malignancy. Cancer 2002;94:1522-1531.